Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases

Abstract

Bevacizumab-based treatment had clinically relevant intracranial activity in the vast majority of patients suffering from recurrent, symptomatic BM. The data supports a prospective clinical trial of bevacizumab as a salvage treatment in BM.